Wainua slows FAP progression in key patient groups: Phase 3 trial
Wainua (eplontersen) is able to slow disease progression and improve life quality for people with familial amyloid polyneuropathy (FAP) regardless of nutritional status, sex, or certain genetic factors. That’s according to new subgroup analyses from the Phase 3 NEURO-TTRansform clinical trial (NCT04136184), whose top-line data supported Wainua’s…